FDA Approves Labeling Update For ORENCIA® (abatacept) To Inhibit Structural Joint Damage In Adults With Moderate To Severe Rheumatoid Arthritis

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ORENCIA® (abatacept) product labeling regarding the progression of structural joint damage — an important measure in the treatment of rheumatoid arthritis (RA). [click link for full article]

Read More: continued here

Filed under: Arthritis on May 7th, 2007